Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development ...

Europe active pharmaceutical ingredients (API) market was valued at $ 49.4 billion in 2022 and will grow by 6.8% annually over 2022-2032, d riven by rising adoption of biologics in disease management, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 70 tables and 52 figures, this 132-page report ?Europe Small Molecule API Market 2022-2032 by Source (Synthetic, ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

The global veterinary eye care market size is estimated to grow by USD 1.05 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.62% during the forecast ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...